India vs South Korea: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
India
97.0%
in 2025
South Korea
97.0%
in 2025
India rank
17th
South Korea rank
17th
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- India
- South Korea
How they compare
India currently reports 97.0% against 97.0% in South Korea, a difference of 0.0%.
Across all 18 years both countries report, South Korea has been ahead every year.
India ranks 17th and South Korea ranks 17th of 194 countries.
South Korea has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | India | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 2.1% | 48.7% | 46.6% | South Korea |
| 2020s | 64.5% | 97.0% | 32.5% | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, India or South Korea?
- India, at 97.0% against 97.0% in South Korea as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between India and South Korea?
- 0.0%, with India ahead.
- How many years of comparable data are there for India and South Korea?
- 18 years are reported by both, from 2008 to 2025.
- How do India and South Korea rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- India ranks 17th and South Korea ranks 17th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.